Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open in the green
Wed, 17 Sep 09:30 am

The major Asian stock markets have opened mainly in the green with the markets in Hong Kong (up 1.1%) and Taiwan (up 1.1%) leading the gains. The Indian share markets have opened the day on a positive note. The sectoral indices are trading mixed with software and consumer durables stocks leading the gains. However, power and oil and gas indices have opened in the red.

The Sensex today is trading higher by around 45 points (0.2%), while the NSE-Nifty is up by about 18 points (0.2%). While mid cap stocks have opened flat, small cap stocks are trading firm with the BSE Small Cap index up by around 0.3%. The rupee is currently trading at Rs 61.02 to the US dollar.

Auto stocks have opened the day on a mixed note with Tube Investments and Maruti Suzuki Ltd leading with losses. However, Escorts Ltd and Force Motors Ltd were leading the gains. As per a leading financial daily, Mr. Mayank Pareek, the Chief Operating Officer (sales & marketing), Maruti Suzuki has put in his papers after serving the company for over two decades. He is a well known as the face of Maruti Suzuki and has been associated with the firm at a time when its market share peaked to its highest for the past five years. His resignation has come ahead of the company's premium sedan, Ciaz's launch, slated in October and at a time when the company is preparing to enter the light commercial vehicle segment. Further, as per the reports, Mr Pareek is likely to move to a rival company.

Indian Pharma stocks have opened the day on a mixed note with Aurobindo Pharma Ltd and Ranbaxy Laboratories Ltd leading the gains. However, J.B Chemicals Ltd and Torrent Pharma Ltd were leading the losses. As per a leading financial daily, Lupin Ltd has entered into a long-term strategic partnership with Merck Serono, the biopharmaceutical division of Merck, for executing the latter's general medicines portfolio expansion initiative in emerging markets. It will be a 10 year long agreement which couldn be renewed. As per the agreement, Lupin will develop products, provide product dossiers and supply finished products to Merck Serono. The latter will then market the products, leveraging its strong commercial and medical teams in emerging markets to bring new medicines in its portfolio to customers. In return, Lupin will receive upfront and milestone based licensing fee. None of the companies has released any financial details of the transaction. The company is also looking at expanding its presence in Russia, Turkey and China, though no definite plan is in place at the moment for the latter.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.